Literature DB >> 24998378

Discovery of triazines as selective PDE4B versus PDE4D inhibitors.

Timothy J Hagen1, Xuesheng Mo2, Alex B Burgin3, David Fox3, Zheng Zhang4, Mark E Gurney5.   

Abstract

In this study we report a series of triazine derivatives that are potent inhibitors of PDE4B. We also provide a series of structure activity relationships that demonstrate the triazine core can be used to generate subtype selective inhibitors of PDE4B versus PDE4D. A high resolution co-crystal structure shows that the inhibitors interact with a C-terminal regulatory helix (CR3) locking the enzyme in an inactive 'closed' conformation. The results show that the compounds interact with both catalytic domain and CR3 residues. This provides the first structure-based approach to engineer PDE4B-selective inhibitors.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Crystallography; PDE4 inhibitor; PDE4B; PDE4D; Triazine

Mesh:

Substances:

Year:  2014        PMID: 24998378      PMCID: PMC4142572          DOI: 10.1016/j.bmcl.2014.06.002

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

Review 1.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

2.  A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.

Authors:  Graeme L Card; Landy Blasdel; Bruce P England; Chao Zhang; Yoshihisa Suzuki; Sam Gillette; Daniel Fong; Prabha N Ibrahim; Dean R Artis; Gideon Bollag; Michael V Milburn; Sung-Hou Kim; Joseph Schlessinger; Kam Y J Zhang
Journal:  Nat Biotechnol       Date:  2005-01-30       Impact factor: 54.908

3.  Discovery of selective PDE4B inhibitors.

Authors:  Kenji Naganuma; Akifumi Omura; Naomi Maekawara; Masahiro Saitoh; Naoto Ohkawa; Takashi Kubota; Hiromitsu Nagumo; Toshiyuki Kodama; Masayoshi Takemura; Yuji Ohtsuka; Junji Nakamura; Ryuichi Tsujita; Koh Kawasaki; Hirotsugu Yokoi; Masashi Kawanishi
Journal:  Bioorg Med Chem Lett       Date:  2009-05-03       Impact factor: 2.823

4.  Discovery of triazines as potent, selective and orally active PDE4 inhibitors.

Authors:  Rainer Gewald; Christian Grunwald; Ute Egerland
Journal:  Bioorg Med Chem Lett       Date:  2013-06-10       Impact factor: 2.823

5.  Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma.

Authors:  S-L Catherine Jin; Sho Goya; Susumu Nakae; Dan Wang; Matthew Bruss; Chiaoyin Hou; Dale Umetsu; Marco Conti
Journal:  J Allergy Clin Immunol       Date:  2010-11-03       Impact factor: 10.793

6.  Structural basis for the design of selective phosphodiesterase 4B inhibitors.

Authors:  David Fox; Alex B Burgin; Mark E Gurney
Journal:  Cell Signal       Date:  2013-12-19       Impact factor: 4.315

7.  Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.

Authors:  Alex B Burgin; Olafur T Magnusson; Jasbir Singh; Pam Witte; Bart L Staker; Jon M Bjornsson; Margret Thorsteinsdottir; Sigrun Hrafnsdottir; Timothy Hagen; Alex S Kiselyov; Lance J Stewart; Mark E Gurney
Journal:  Nat Biotechnol       Date:  2009-12-27       Impact factor: 54.908

Review 8.  Keynote review: phosphodiesterase-4 as a therapeutic target.

Authors:  Miles D Houslay; Peter Schafer; Kam Y J Zhang
Journal:  Drug Discov Today       Date:  2005-11-15       Impact factor: 7.851

Review 9.  Phosphodiesterase 4-targeted treatments for autoimmune diseases.

Authors:  Neal Kumar; Ari M Goldminz; Noori Kim; Alice B Gottlieb
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

  9 in total
  14 in total

1.  New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies.

Authors:  Sara Guariento; Olga Bruno; Paola Fossa; Elena Cichero
Journal:  Mol Divers       Date:  2015-08-20       Impact factor: 2.943

2.  Phosphodiesterase 4 inhibitors and drugs of abuse: current knowledge and therapeutic opportunities.

Authors:  Christopher M Olsen; Qing-Song Liu
Journal:  Front Biol (Beijing)       Date:  2016-10-17

3.  Selective Inhibition of PDE4B Reduces Methamphetamine Reinforcement in Two C57BL/6 Substrains.

Authors:  Kevin M Honeywell; Eliyana Van Doren; Karen K Szumlinski
Journal:  Int J Mol Sci       Date:  2022-04-28       Impact factor: 6.208

Review 4.  PDE4 subtypes in cancer.

Authors:  Samuel Hsien Lai; Guston Zervoudakis; Jesse Chou; Mark E Gurney; Kelly M Quesnelle
Journal:  Oncogene       Date:  2020-03-20       Impact factor: 9.867

Review 5.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

Review 6.  Cardiac cAMP: production, hydrolysis, modulation and detection.

Authors:  Cédric Boularan; Céline Gales
Journal:  Front Pharmacol       Date:  2015-10-01       Impact factor: 5.810

7.  Identification of a multifunctional docking site on the catalytic unit of phosphodiesterase-4 (PDE4) that is utilised by multiple interaction partners.

Authors:  Kirsty F Houslay; Frank Christian; Ruth MacLeod; David R Adams; Miles D Houslay; George S Baillie
Journal:  Biochem J       Date:  2016-12-19       Impact factor: 3.857

8.  Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury.

Authors:  Nicole M Wilson; Mark E Gurney; W Dalton Dietrich; Coleen M Atkins
Journal:  PLoS One       Date:  2017-05-19       Impact factor: 3.240

9.  Selective Inhibition of PDE4B Reduces Binge Drinking in Two C57BL/6 Substrains.

Authors:  C Leonardo Jimenez Chavez; Camron D Bryant; Melissa A Munn-Chernoff; Karen K Szumlinski
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

10.  Pyridazinone derivatives as potential anti-inflammatory agents: synthesis and biological evaluation as PDE4 inhibitors.

Authors:  Ingrid Allart-Simon; Aurélie Moniot; Nicolo Bisi; Miguel Ponce-Vargas; Sandra Audonnet; Marie Laronze-Cochard; Janos Sapi; Eric Hénon; Frédéric Velard; Stéphane Gérard
Journal:  RSC Med Chem       Date:  2021-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.